Dr. Mato on the Benefits of the JTCC Retrospective Trial
Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial
Anthony R. Mato, MD, attending physician, Division of Lymphoma, John Theurer Cancer Center (JTCC) at Hackensack University Medical Center, discusses the retrospective outcome investigation of 938 patients receiving consecutive allogeneic and autologous hematopoietic stem cell transplantation (ASCT).
High-dose therapy and ASCT are the current standards of care for chemo-sensitive relapsed diffuse large B-cell lymphoma and Hodgkin lymphoma. The study looked at information gathered from the past two decades (1990-2011) at the JTCC. The retrospective look at the data helped illuminate potential areas for improvement and future clinical trials.
Mato believes the data helped validate advances made in allogeneic transplantation in the past decade by demonstrating improved outcomes. The patients that benefited were heavily pretreated, relapsed or refractory, and in some cases already had received ASCT.
